Last reviewed · How we verify
Trilisate (CHOLINE MAGNESIUM TRISALICYLATE)
Trilisate works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation.
Trilisate, also known as choline magnesium trisalicylate, is a small molecule drug in the salicylate class. It is used to treat various conditions including fever, osteoarthritis, pain, rheumatoid arthritis, and shoulder tendonitis. The commercial status of Trilisate is unknown, but it is likely available as a generic medication. Key safety considerations include potential gastrointestinal side effects and interactions with other medications. As a salicylate, Trilisate works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.
At a glance
| Generic name | CHOLINE MAGNESIUM TRISALICYLATE |
|---|---|
| Drug class | choline magnesium trisalicylate |
| Therapeutic area | Immunology |
| Phase | discontinued |
Mechanism of action
Imagine your body has a fire alarm system that goes off when there's an injury or infection. Prostaglandins are like the alarm signals that tell your body to send in the pain and inflammation fighters. Trilisate blocks these alarm signals, so your body doesn't send in the pain and inflammation fighters as much, which helps to reduce pain and inflammation.
Approved indications
- Fever
- Osteoarthritis
- Pain
- Rheumatoid arthritis
- Shoulder Tendonitis
Common side effects
- irreversible hearing loss and/or tinnitus
- mental confusion and hallucinations
- hepatitis
- elevated hepatic transaminases
- esophagitis
- asthma
- erythema multiforme
- urticaria
- ecchymoses
- duodenal ulceration
Key clinical trials
- Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (PHASE2)
- Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies (PHASE2)
- Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trilisate CI brief — competitive landscape report
- Trilisate updates RSS · CI watch RSS